Pharmaceutical Product Monograph: Fluphenazine Decanoate / HCl (25 mg/mL)
In the pharmaceutical industry, Fluphenazine is a high-potency Typical (First-Generation) Antipsychotic belonging to the Piperazine Phenothiazine class. As a pharmacist and manufacturer, I view this molecule as the “Long-Acting Maintenance Standard”—it is technically designed to provide sustained dopamine blockade, particularly in its esterified (Decanoate) form, which allows for dosing intervals of several weeks.
At your WHO-GMP facility in Mumbai, Fluphenazine is a critical SKU for Psychiatric and Mental Health portfolios. While newer “atypical” antipsychotics exist, Fluphenazine remains a cost-effective, highly potent “Gold Standard” for chronic schizophrenia management in many international B2B markets.
Therapeutic Profile: Primary Indications
Fluphenazine is indicated for the management of manifestations of psychotic disorders.
| Indication | Clinical Context | Technical Rationale |
| Chronic Schizophrenia | Maintenance Therapy | Decanoate Form: Used to prevent relapse in patients who are non-compliant with daily oral medication. |
| Acute Psychosis | Emergency Psychiatry | HCl Form: Used for rapid “tranquilization” of agitated or aggressive patients in a hospital setting. |
| Schizoaffective Disorder | Stabilization | Controls the “positive” symptoms like hallucinations, delusions, and disorganized thinking. |
Mechanism: Potent D2 Receptor Antagonism
Fluphenazine works by “muting” overactive dopamine signaling in the brain:
Dopamine Blockade: It acts as a powerful antagonist at Post-synaptic Dopamine D2 receptors.
Mesolimbic Pathway: By blocking D2 receptors in this specific pathway, it reduces the “positive” symptoms of schizophrenia (hallucinations/delusions).
High Potency: Technically, Fluphenazine has a very high affinity for the D2 receptor, meaning very small doses (milligram for milligram) are required compared to older drugs like Chlorpromazine.
Alpha-1 & Histamine Effects: It also has some blocking effect on alpha-adrenergic and histaminergic receptors, which contributes to its side-effect profile.
The Pharmacist’s “Technical Warning”
The “EPS” Risk: As a pharmacist, I must emphasize that high-potency D2 blockers have a very high risk of Extrapyramidal Symptoms (EPS). This includes acute dystonia (muscle spasms), akathisia (restlessness), and parkinsonism.
Tardive Dyskinesia: Long-term use carries a risk of Tardive Dyskinesia—involuntary, repetitive movements of the tongue and face—which may be irreversible.
Neuroleptic Malignant Syndrome (NMS): This is a rare but fatal technical complication characterized by “lead-pipe” muscle rigidity, high fever, and autonomic instability.
The “Test Dose” Protocol: For the Decanoate (long-acting) injection, a small “test dose” of oral fluphenazine or a short-acting injection is technically required to ensure the patient does not have a severe adverse reaction before the 4-week dose is administered.
The Manufacturer’s Perspective: Technical & Export
From a production and B2B standpoint at your facility in Mumbai:
The “Decanoate Ester” USP: Fluphenazine Decanoate is an Oil-based (Sesame or Castor Oil) injection. On your digital marketplace, highlight your Lipid-Solubility Stabilization. This is the technical key to the “Depot” effect, where the drug is released slowly from the muscle over 2 to 4 weeks.
The “B2B Mental Health” Market: Market Fluphenazine to Government Health Ministries and NGOs as a “Compliance-Enhancing Tool.” Its long-acting nature significantly reduces re-hospitalization rates, making it a “High-Value Social Impact” drug.
Dossier Support: We provide full WHO-standard CTD/eCTD Dossiers for Fluphenazine Decanoate 25 mg/mL and Fluphenazine HCl 2.5 mg/mL to support your registration in international B2B psychiatric tenders.